Exposure to Glyphosate Leads to Hematologic Malignancies in Patients

Case Overview

This case revolves around multiple individuals who were exposed to glyphosate, a known herbicide found in Roundup, over an extended period. Following this exposure, these patients developed hematologic malignancies, primarily Non-Hodgkin's lymphoma (NHL). As their legal counsel, we seek an expert in Hematology/Oncology to provide insights into the causation of these malignancies related to glyphosate exposure.

Questions to the Oncology expert and their responses

How often do you evaluate and manage patients who have been diagnosed with Non-Hodgkin's lymphoma (NHL)?

I see about 12 Non-Hodgkin's lymphoma patients weekly.

Have you previously been involved in the Monsanto/Roundup litigation? If yes, please elaborate.

I have over the past year served as an expert witness in Monsanto litigation concerning the causation of NHL working with many of the top firms in the nation on these matters including Baum Hedlund, Weitz, Luxenberg, Wagstaff Law, etc. In these matters, I have authored differential causation reports demonstrating by process of elimination that glyphosate is the primary causative factor in the patients' lymphomas. I have been deposed and my first trial appearance in these matters is scheduled for next month. I am extremely well qualified to review these matters for causation and familiar with the glyphosate literature. I would be happy to assist with this case.

About the expert

This expert has over 25 years of experience in medical oncology, specializing in melanomas and sarcomas. He earned his BS in chemical engineering from Auburn University, before receiving his MD from the University of Alabama at Birmingham. He then completed a residency in internal medicine and a fellowship in hematology and oncology at the University of Alabama at Birmingham. Today, this expert is board-certified in medical oncology and is a member of several professional organizations, including the American Society of Clinical Oncology and the Cancer Center Sarcoma Working Group. He is very active in academia, holding 1 patent and authoring more than 70 peer-reviewed journal articles and 60 abstracts on topics pertaining to medical oncology. Moreover, he has conducted clinical trials for most malignancies, including breast, colon, lung, and prostate cancer. Previously, he was an associate professor of pathology, the program director of melanoma and sarcoma, the chairman of the cancer center melanoma working group, and the medical director of the immune cytopenia laboratory at the University of Alabama at Birmingham. Additionally, he was an associate scientist and an attending medical oncologist at the Comprehensive Cancer Center, also at the University of Alabama at Birmingham. Currently, he serves as a medical oncologist and hematologist at a private practice in Alabama.

E-051463

Specialties:

Oncology